Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Pramlintide

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

AstraZeneca · Phase 2 · Completed · Enrollment 636

NCT00673387

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
Placebo-P + Placebo-M4 participants0 participants5 participantsn/rn/r
Pramlintide 360 mcg + Placebo-M31 participants6 participants5 participantsn/rn/r
Placebo-P + Metreleptin 5.0 mg4 participants3 participants3 participantsn/rn/r
Pramlintide 180 mcg + Metreleptin 2.5 mg27 participants0 participants5 participantsn/rn/r
Pramlintide 180 mcg + Metreleptin 5.0 mg21 participants2 participants4 participantsn/rn/r
Pramlintide 360 mcg + Metreleptin 1.25 mg26 participants5 participants4 participantsn/rn/r
Pramlintide 360 mcg + Metreleptin 2.5 mg29 participants1 participants7 participantsn/rn/r
Pramlintide 360 mcg + Metreleptin 5.0 mg19 participants1 participants3 participantsn/rn/r

A count stays a count. This page does not turn a count into a percent.